real-world-study-finds-dupilumab-reduces-itch-in-chronic-prurigo-nodularis
Real-World Study Finds Dupilumab Reduces Itch in Chronic Prurigo Nodularis

Real-World Study Finds Dupilumab Reduces Itch in Chronic Prurigo Nodularis

A real-world observational study conducted in routine clinical practice demonstrates that dupilumab provides substantial, durable clinical improvement for adult patients suffering from moderate-to-severe chronic prurigo nodularis. Published in Dermatology and Therapy by Laura Parra-Navarro and colleagues from a tertiary hospital in Spain, the retrospective evaluation showed that targeted inhibition of type 2 neuro-immune signaling achieved clinically meaningful reductions in intractable pruritus and cleared or almost cleared severe nodular skin lesions. Beyond confirming the therapeutic efficacy established in earlier randomized clinical trials, the clinical cohort provides critical real-world insights into practical long-term management, highlighting both the feasibility of extending maintenance dosing intervals in patients who attain stable disease control and the distinctive role that psychiatric comorbidities play in modulating therapeutic response.

Chronic prurigo nodularis represents a severely debilitating, multidimensional neuro-immunocutaneous disease characterized by persistent, agonizing itch lasting at least six weeks, chronic scratching behavior, and the progressive development of hard, excoriated pruriginous papules and nodules. The condition inflicts a profound multidimensional burden on affected individuals, systematically disrupting sleep architecture, causing severe emotional distress, and drastically impairing day-to-day functional quality of life. At the biological level, current scientific evidence establishes that chronic prurigo nodularis is driven by complex interactions among immune dysregulation, structural neural alterations, and profibrotic tissue remodeling that perpetuate a self-reinforcing itch–scratch cycle. Within this pathway, type 2 inflammatory signaling plays an indispensable role, as upregulated expression of interleukins IL-4, IL-13, and IL-31 mediates epidermal hyperplasia, promotes extensive dermal inflammation and fibrosis, and directly activates and sensitizes peripheral pruriceptive sensory neurons.

Traditional therapeutic strategies for chronic prurigo nodularis rely upon interdisciplinary regimens combining intensive topical anti-inflammatory formulations, phototherapy, and systemic agents such as gabapentinoids, antidepressants, and broad immunosuppressants. However, many of these options are limited by variable effectiveness, tolerability concerns, and the need for prolonged treatment in patients with substantial comorbidity and treatment burden. Dupilumab, a fully human monoclonal antibody directed specifically against the shared interleukin-4 receptor alpha subunit, blocks the downstream signaling of both IL-4 and IL-13. Although approved in the European Union for adults with moderate-to-severe chronic prurigo nodularis requiring systemic intervention following the pivotal PRIME and PRIME2 clinical trials, real-world data tracking patient outcomes in unselected clinic populations—especially regarding flexible dosing intervals, long-term safety, and baseline predictive markers—have remained sparse.

To address these evidentiary gaps, the Spanish research team conducted a single-center, retrospective observational study encompassing 26 consecutive adult patients diagnosed with moderate-to-severe chronic prurigo nodularis according to the 2024 Spanish consensus criteria who commenced dupilumab therapy between March 2023 and July 2025. Standard treatment protocols were adhered to, initiating with a 600-milligram subcutaneous loading dose followed by maintenance injections of 300 milligrams administered every two weeks. The study cohort reflected an intensely burdened population: the median patient age was 50 years at diagnosis and 45.5 years at treatment initiation, 65 percent were female, and the median body mass index was 26.37 kilograms per square meter. Patients had received a median of three previous systemic treatments before initiating dupilumab.

Baseline assessments revealed extensive cutaneous and psychological disease activity across the cohort. At treatment entry, 81 percent of participants presented with an Investigator’s Global Assessment for Prurigo Nodularis-Stage score of 3, while 19 percent exhibited stage 4 disease, with nodules predominantly distributed across the legs in 96 percent and arms in 77 percent of individuals across a median of two affected anatomical territories. Median baseline scores on the Worst Itch–Numeric Rating Scale and the sleep disturbance numeric scale were both elevated at 8 on a ten-point scale, while the median Dermatology Life Quality Index reached 19, denoting severe impairment. Concurrently, baseline psychological profiling identified psychiatric comorbidities in 73 percent of patients, primarily comprising generalized anxiety, clinical depression, mixed anxiety-depressive disorder, and neurotic excoriations, accompanied by median Hospital Anxiety and Depression Scale total scores of 17 and median Barratt Impulsiveness Scale scores of 60.5.

Therapeutic effectiveness evaluated at the primary milestone of week 24 revealed marked, clinically meaningful relief. Among the 22 evaluable patients at this time point, 59 percent achieved the primary endpoint of at least a four-point reduction on the Worst Itch–Numeric Rating Scale, reflecting substantial relief from chronic itch. In standardized sensitivity evaluations using nonresponder imputation, 54 percent achieved this primary pruritus threshold, while an extended nonresponder imputation model incorporating all 26 enrolled subjects confirmed a 50 percent response rate. Concurrently, 45 percent of evaluable patients achieved clear or almost clear skin status, defined by an Investigator’s Global Assessment score of 0 or 1, and an identical 45 percent met the stringent combined endpoint requiring simultaneous clearance of skin nodules alongside a four-point or greater reduction in pruritus intensity.

Longitudinal monitoring demonstrated that symptom improvement commenced early and consolidated with continued exposure across follow-up, which spanned a median of 50 weeks and reached up to 168 weeks. As early as week 12, 58 percent of patients had already attained a meaningful four-point reduction in itch scores, 77 percent exhibited partial nodular reduction, and 31 percent attained complete skin clearance. By week 36, among 17 evaluable individuals, 71 percent achieved itch response and 53 percent attained stage 0 or 1 skin clearance. At week 48, among 13 evaluable patients, the proportion reaching a four-point itch reduction rose to 85 percent, while 77 percent maintained clear or almost clear nodular stages alongside complete combined response. Nonparametric Friedman testing confirmed statistically significant improvements across itch severity, Investigator’s Global Assessment stages, sleep quality ratings, and quality of life scores across baseline, week 12, and week 24.

The cohort also documented meaningful downward adjustments in concomitant medications as biological disease control took hold. At treatment initiation, 65.4 percent of patients required neuromodulatory therapies, including 53.8 percent prescribed antidepressants and half the cohort taking two or more psychoactive or neuromodulatory compounds. Topical corticosteroid reliance steadily fell from 69.2 percent of patients at baseline to 40.9 percent by week 24, dropping further to 30.8 percent at week 48. Concurrently, adjunctive prescription of benzodiazepines dropped from 19.2 percent at initiation down to 4.5 percent at week 24 and 0.0 percent at week 48.

A critical contribution of the investigation centered on real-world patterns of dupilumab dosing-interval extension. In nine patients who achieved robust clinical control, clinicians attempted dosing prolongation after a median treatment duration of 32.9 weeks, initially lengthening injection frequency to 300 milligrams every three weeks. At the time of this initial extension, 88.9 percent of candidates had achieved an Investigator’s Global Assessment score of 0 or 1. Four patients subsequently advanced to an extended schedule of 300 milligrams every four weeks after a median of 64.5 weeks. While four of the nine patients experienced symptom recrudescence requiring a return to the standard every-two-week regimen without necessitating a secondary loading dose, five patients successfully maintained prolonged dosing without relapse over a median follow-up of 23 weeks, uniformly preserving clear or almost clear skin. All successful maintainers had achieved both skin clearance and major itch relief at week 24 and required significantly less topical corticosteroid co-medication.

Multivariable statistical modeling using penalized logistic regression with Firth correction uncovered a notable prognostic relationship regarding baseline characteristics and therapeutic outcomes. While baseline parameters such as initial itch score, baseline quality of life, immunoglobulin E, lactate dehydrogenase, and demographic features did not predict response, the presence of baseline psychiatric comorbidity was significantly associated with reduced odds of achieving the primary week-24 itch endpoint, yielding an odds ratio of 0.01. The investigators emphasized that this statistical association must not be viewed as a rationale to withhold biologic therapy from psychiatric patients, but rather as empirical evidence that overlapping neurobehavioral mechanisms influence perceived symptom relief, underscoring the vital clinical necessity of integrated, multidisciplinary psychodermatological support.

Safety outcomes throughout the observation window were reassuring and aligned with the favorable tolerability established in clinical trials. Adverse events potentially related to dupilumab emerged in only two patients, representing 7.7 percent of the cohort. One individual developed xerophthalmia and xerostomia that did not require drug cessation, while a second patient experienced a gastrointestinal disorder that prompted treatment discontinuation. Notably, no cases of conjunctivitis were recorded. Overall, six patients discontinued dupilumab across the observation timeline, driven by personal patient preference in three cases, adverse event in one, loss to follow-up in one, and elective transition to lebrikizumab in one patient who experienced atopic dermatitis exacerbation despite excellent control of chronic prurigo nodularis.

In evaluating their conclusions, the investigators recognized clear methodological constraints inherent to the study, including its retrospective single-center framework, small cohort size, absence of a parallel control cohort, and diminished sample size at later time points introducing potential survivor bias. Nevertheless, the findings support the effectiveness and safety of dupilumab for moderate-to-severe chronic prurigo nodularis across pruritus, clinical severity, and quality-of-life outcomes. By documenting the viability of carefully monitored, reversible dose-spacing strategies and confirming the critical influence of mental health comorbidity on therapeutic outcomes, this real-world evidence establishes a compelling foundation for individualized, multidisciplinary treatment paradigms in chronic prurigo nodularis.

Subject of Research: Real-world effectiveness, safety, and prolonged dosing intervals of dupilumab in moderate-to-severe chronic prurigo nodularis

Article Title: Dupilumab for Moderate-to-Severe Chronic Prurigo Nodularis: A Retrospective Real-World Study of Effectiveness, Safety, and Prolonged Dosing Intervals

Article References: Parra-Navarro, L., Berna-Rico, E., Bertolín-Colilla, M., Ciudad-Moro, A., Rivera-Lopez, M., Mohammad-Porras, N., García-Díez, I., Pujol, R. M., Gallardo-Hernandez, F., & Tribó-Boixareu, M. J. (2026). Dupilumab for Moderate-to-Severe Chronic Prurigo Nodularis: A Retrospective Real-World Study of Effectiveness, Safety, and Prolonged Dosing Intervals. Dermatology and Therapy. https://doi.org/10.1007/s13555-026-01893-w

Image Credits: AI Generated

DOI: 10.1007/s13555-026-01893-w

Keywords: Dupilumab, Chronic prurigo nodularis, Pruritus, Dermatology, Type 2 inflammation, Interleukin-4 receptor, Interleukin-13, Worst Itch Numeric Rating Scale, Investigator Global Assessment, Dermatology Life Quality Index, Neuroimmunology, Real-world evidence, Dosing intervals, Psychiatric comorbidity, Sleep disturbance, Hospital Anxiety and Depression Scale, Barratt Impulsiveness Scale